LakeShore Biopharma Co (FRA:H6Z0) Piotroski F-Score: 0 (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:H6Z0 LakeShore Biopharma Co Ltd FRA:H6Z0
17 GF Score
Price €0.67
View Full Analysis

What is LakeShore Biopharma Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

LakeShore Biopharma Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for LakeShore Biopharma Co's Piotroski F-Score or its related term are showing as below:

LakeShore Biopharma Co  (FRA:H6Z0) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


LakeShore Biopharma Co Piotroski F-Score Related Terms


LakeShore Biopharma Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Piotroski F-Score Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Piotroski F-Score
N/A N/A 4.00 3.00 4.00

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only 4.00 0.00 3.00 0.00 4.00
FRA:H6Z0
17GF Score
LakeShore Biopharma Co Ltd FRA:H6Z0
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Net Income was €-12.76 Mil.
Cash Flow from Operations was €-15.44 Mil.
Revenue was €78.47 Mil.
Gross Profit was €64.72 Mil.
Average Total Assets from the begining of this year (Mar24)
to the end of this year (Mar25) was (193.291 + 174.512) / 2 = €183.9015 Mil.
Total Assets at the begining of this year (Mar24) was €193.29 Mil.
Long-Term Debt & Capital Lease Obligation was €3.00 Mil.
Total Current Assets was €107.47 Mil.
Total Current Liabilities was €105.24 Mil.
Net Income was €-55.38 Mil.

Revenue was €73.26 Mil.
Gross Profit was €58.22 Mil.
Average Total Assets from the begining of last year (Mar23)
to the end of last year (Mar24) was (233.097 + 193.291) / 2 = €213.194 Mil.
Total Assets at the begining of last year (Mar23) was €233.10 Mil.
Long-Term Debt & Capital Lease Obligation was €12.87 Mil.
Total Current Assets was €115.38 Mil.
Total Current Liabilities was €102.49 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

LakeShore Biopharma Co's current Net Income (TTM) was -12.76. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

LakeShore Biopharma Co's current Cash Flow from Operations (TTM) was -15.44. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar24)
=-12.758/193.291
=-0.06600411

ROA (Last Year)=Net Income/Total Assets (Mar23)
=-55.376/233.097
=-0.23756634

LakeShore Biopharma Co's return on assets of this year was -0.06600411. LakeShore Biopharma Co's return on assets of last year was -0.23756634. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

LakeShore Biopharma Co's current Net Income (TTM) was -12.76. LakeShore Biopharma Co's current Cash Flow from Operations (TTM) was -15.44. ==> -15.44 <= -12.76 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=2.999/183.9015
=0.01630764

Gearing (Last Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=12.873/213.194
=0.06038162

LakeShore Biopharma Co's gearing of this year was 0.01630764. LakeShore Biopharma Co's gearing of last year was 0.06038162. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar25)=Total Current Assets/Total Current Liabilities
=107.466/105.237
=1.02118076

Current Ratio (Last Year: Mar24)=Total Current Assets/Total Current Liabilities
=115.381/102.485
=1.12583305

LakeShore Biopharma Co's current ratio of this year was 1.02118076. LakeShore Biopharma Co's current ratio of last year was 1.12583305. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

LakeShore Biopharma Co's number of shares in issue this year was 19.159. LakeShore Biopharma Co's number of shares in issue last year was 10.692. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=64.717/78.468
=0.82475659

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=58.22/73.255
=0.79475804

LakeShore Biopharma Co's gross margin of this year was 0.82475659. LakeShore Biopharma Co's gross margin of last year was 0.79475804. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar24)
=78.468/193.291
=0.40595786

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar23)
=73.255/233.097
=0.31426831

LakeShore Biopharma Co's asset turnover of this year was 0.40595786. LakeShore Biopharma Co's asset turnover of last year was 0.31426831. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+1+0+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

LakeShore Biopharma Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.


LakeShore Biopharma Co Business Description

Other Exchanges LSBCF:USA
Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
17GF Score

Get the complete analysis for FRA:H6Z0

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.67
Price